Andrew J Yee
Overview
Explore the profile of Andrew J Yee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1560
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Katznelson E, Jerosch-Herold M, Cuddy S, Clerc O, Benz D, Taylor A, et al.
Front Cardiovasc Med
. 2024 Jun;
11:1371810.
PMID: 38873265
Background: Cardiac systolic dysfunction is a poor prognostic marker in light-chain (AL) cardiomyopathy, a primary interstitial disorder; however, its pathogenesis is poorly understood. Purpose: This study aims to analyze the...
12.
ODonnell E, Mo C, Yee A, Nadeem O, Laubach J, Rosenblatt J, et al.
Lancet Haematol
. 2024 Apr;
11(6):e415-e424.
PMID: 38677302
Background: Isatuximab is a CD38 monoclonal antibody approved for relapsed or refractory multiple myeloma. We aimed to evaluate the addition of isatuximab to weekly carfilzomib (K), lenalidomide (R), and dexamethasone...
13.
Boulanger M, Tieger M, Eliott D, Yee A
EJHaem
. 2024 Apr;
5(2):421-422.
PMID: 38633109
No abstract available.
14.
Al Jurdi A, Cohen Bucay A, Riella L, Yee A, Abdelmalek C, Klepeis V, et al.
Transplant Direct
. 2024 Apr;
10(5):e1616.
PMID: 38606352
No abstract available.
15.
Datar Y, Clerc O, Cuddy S, Kim S, Taylor A, Canseco Neri J, et al.
Eur Heart J Cardiovasc Imaging
. 2024 Jan;
25(5):687-697.
PMID: 38193678
Aims: In systemic light-chain (AL) amyloidosis, quantification of right ventricular (RV) amyloid burden has been limited and the pathogenesis of RV dysfunction is poorly understood. Using 18F-florbetapir positron emission tomography/computed...
16.
Ababneh H, Yee A, Raje N, Martin S, Frigault M, Ng A, et al.
Radiother Oncol
. 2023 Oct;
189:109933.
PMID: 37778534
Radiation therapy (RT) may play an important role prior to and following BCMA-targeted CAR T-cell therapy in multiple myeloma (MM). We report a series of 13 patients: 5 patients received...
17.
Jagannath S, Anderson M, Yee A, Hasserjian R
N Engl J Med
. 2023 Sep;
389(12):1133-1143.
PMID: 37733312
No abstract available.
18.
Mo C, Yee A, Midha S, Hartley-Brown M, Nadeem O, ODonnell E, et al.
EJHaem
. 2023 Aug;
4(3):792-810.
PMID: 37601856
Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin-1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for...
19.
Karschnia P, Miller K, Yee A, Rejeski K, Johnson P, Raje N, et al.
Blood
. 2023 Jul;
142(14):1243-1248.
PMID: 37471607
No abstract available.
20.
Graham C, Lee W, Wiggin H, Supper V, Leick M, Birocchi F, et al.
Blood
. 2023 Jul;
142(14):1248-1252.
PMID: 37467494
No abstract available.